Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AT-01 (Axcynsis Therapeutics)
- Development stage
- Preclinical
- Lead developer
- Axcynsis Therapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AT-01 is an antibody-drug conjugate (ADC) developed by Axcynsis Therapeutics that targets Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1). The drug is constructed using the company's proprietary Antibody-X Conjugate (AXC) platform and incorporates the AxcynDOT cytotoxic payload. ROR1 is an onco-embryonic protein that is highly expressed in various hematological and solid malignancies but is largely absent from healthy adult tissues, making it a highly selective target for cancer therapy. AT-01 is designed to bind to ROR1 on the surface of tumor cells, undergo internalization, and release its potent AxcynDOT payload to induce targeted cell death while minimizing off-target toxicity.
- Other names
- AT-01-Axcynsis Therapeutics-ROR1-ADCAT01-Axcynsis Therapeutics-ROR1-ADCAT 01-Axcynsis Therapeutics-ROR1-ADC
02
Targets
ROR1 (Receptor tyrosine kinase-like orphan receptor 1)
Beyond the preview
Go deeper on AT-01 (Axcynsis Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AT-01 (Axcynsis Therapeutics).